Tolerability of inhaled mannitol in children with cystic fibrosis: initiation dose assessment

Despite active discussion in different countries of the world about possible reduction of the amount of basic therapy of cystic fibrosis due to the use of CFTR-modulators, in particular mucolytics, many patients continue mucolytic inhalation therapy, including mannitol. The aim. A retrospective evaluation of the tolerability of the inhaled mannitol (Bronchitol Pharmaxis, GEN Ilac, Turkey) in children with cystic fibrosis (cwCF). Methods. 142 cwCF aged from 6 to 17 years (62 boys) who underwent inpatient treatment at the Separate Structural Unit Russian Children’s Clinical Hospital of the Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Ministry of Health of the Russian Federation from 2021 to 2023 were administered the initial dose assessment BIDA test. Results. Most cases demonstrated good tolerability and pronounced mucolytic effect when using the study drug. Isolated cases of intolerance (6.3%) in the form of acute bronchobstructive syndrome were observed. Conclusion. The presented evaluation of the effect of an initial dose of inhaled mannitol in a sufficiently large cohort of cwCF of different ages clearly illustrates the high safety and efficacy profile of the study drug.

1. Taylor-Cousar J.L., Robinson P.D., Shteinberg M., Downey D.G. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet. 2023; 402 (10408): 1171–1184. DOI: 10.1016/s0140-6736(23)01609-4.

2. Hisert K.B., Birket S.E., Clancy J.P. et al. Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy. Lancet Respir. Med. 2023; 11 (10): 916–931. DOI: 10.1016/s2213-2600(23)00324-7.

3. Bower J.K., Volkova N., Ahluwalia N. et al. Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study. J. Cyst. Fibros. 2023; 22 (4): 730737. DOI: 10.1016/j.jcf.2023.03.002.

4. Sawicki L.T., Altenburg G.S. et al. Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis. J. Cyst. Fibros. 2023; 22 (3): 402–406. DOI: 10.1016/j.jcf.2022.12.009.

5. Mok L.C., Garcia-Uceda A., Cooper M.N. et al. The effect of CFTR modulators on structural lung disease in cystic fibrosis. Front. Pharmacol. 2023; 14: 1147348. DOI: 10.3389/fphar.2023.1147348.

6. De Vuyst R.C., Bennard E., Kam C.W. et al. Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis. Pediatr. Pulmonol. 2023; 58 (5): 1592–1594. DOI: 10.1002/ppul.26334.

7. Daviskas E., Rubin B.K. Effect of inhaled dry powder mannitol on mucus and its clearance. Expert Rev. Respir. Med. 2013; 7 (1): 65–75. DOI: 10.1586/ers.12.72.

8. Kashirskaya N.Yu., Kapranov N.I., Kondratyeva E.I., eds. [Mukoviscidosis (cystic fibrosis)]. 2nd Edn. Moscow: Medpractika-M; 2021 (in Russian).

9. De Boeck K., Haarma, E., Hull J. et al. Inhaled dry powder mannitol in children with cystic fibrosis: a randomised efficacy and safety trial. J. Cyst. Fibros. 2017; 16 (3): 380–387. DOI: 10.1016/j.jcf.2017.02.003.

10. Ademhan Tural D., Yalçın E., Emiralioglu N. et al. Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis. Pediatr. Pulmonol. 2022; 57 (1): 142–151. DOI: 10.1002/ppul.25740.

11. Kerem E., Viviani L., Zoli, A. et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur. Respir. J. 2014; 43 (1): 125–133. DOI: 10.1183/09031936.00166412.

12. Shoff S.M., Tluczek A., Laxova A. et al. Nutritional status is associated with health-related quality of life in children with cystic fibrosis aged 9–19 years. J. Cyst. Fibros. 2013; 12 (6): 746–753. DOI: 10.1016/j.jcf.2013.01.006.

13. Stephenson A.L., Mannik L.A., Walsh S. et al. Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study. Am. J. Clin. Nutr. 2013; 97 (4): 872–877. DOI: 10.3945/ajcn.112.051409.

14. Wilschanski M., Munc, A., Carrion E. et al. ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis. Clin. Nutr. 2024; 43 (2): 413–445. DOI: 10.1016/j.clnu.2023.12.017.

15. Tümmler B. Post-approval studies with the CFTR modulators Elexacaftor–Tezacaftor–Ivacaftor. Front. Pharmacol. 2023; 14: 1158207. DOI: 10.3389/fphar.2023.1158207.

16. Altabee R., Mwamba M.J., Turner D. et al. Measurement of treatment burden in cystic fibrosis: a systematic review. J. Cyst. Fibros. 2024; S1569–1993(24)01812-5. DOI: 10.1016/j.jcf.2024.11.005.

17. Sawicki G.S., Sellers D.E., Robinson W.M. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J. Cyst. Fibros. 2009; 8 (2): 91–96. DOI: 10.1016/j.jcf.2008.09.007.

18. Southern K.W., Addy C., Bell S.C. et al. Standards for the care of people with cystic fibrosis; establishing and maintaining health. J. Cyst. Fibros. 2024; 23 (1): 12–28. DOI: 10.1016/j.jcf.2023.12.002.

19. Burgel P.R., Southern K.W., Addy C. et al. Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues. J. Cyst. Fibros. 2024; 23 (2): 187–202. DOI: 10.1016/j.jcf.2024.01.005.

20. Ademhan Tural D., Yalçın E., Emiralioglu N. et al. Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis. Pediatr. Pulmonol. 2022; 57 (1): 142–151. DOI: 10.1002/ppul.25740.

21. Tiddens H.A.W.M., Chen Y., Andrinopoulou E.R. et al. The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. Lancet Respir. Med. 2022; 10 (7): 669–678. DOI: 10.1016/S2213-2600(21)00546-4.

22. Flume P.A., Amelina E., Daines, C.L. et al. Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: an international, randomized controlled study. J. Cyst. Fibros. 2021; 20 (6): 1003–1009. DOI: 10.1016/j.jcf.2021.02.011.

23. Flume P.A., Aitken M.L., Bilton D. et al. Optimising inhaled mannitol for cystic fibrosis in an adult population. Breathe (Sheff.). 2015; 11 (1): 39–48. DOI: 10.1183/20734735.021414.

24. Shadrina V.V., Zhekaite E.K., Voronkova A.Yu. et al. [Tolerability of the first inhaled mannitol dose in children with cystic fibrosis]. Pul’monologiya. 2024; 34 (4): 515–521. DOI: 10.18093/0869-0189-2024-34-4-515-521 (in Russian).

25. Simonova O.I., Gorinova Y.V., Vysokolova O.V. et al. [Mannitol therapy for children with cystic fibrosis: efficacy and safety]. Meditsinskiy sovet. 2022; 16 (18): 56–63. DOI: 10.21518/2079-701X-2022-16-18-56-63 (in Russian).